Week in Review: Suzhou Connect Biopharma In-Licenses Anti-Inflammatories from Arena
22:07 EDT 28 Jul 2012 | ChinaBio Today
Suzhou Connect Biopharma, a new startup, in-licensed two series of anti-inflammatory compounds from Arena Pharma of San Diego; Transgene of France and China’s Tasly Pharma announced their JV will develop four of Transgene’s biotech imm..
Original Article: Week in Review: Suzhou Connect Biopharma In-Licenses Anti-Inflammatories from Arena
More From BioPortfolio on "Week in Review: Suzhou Connect Biopharma In-Licenses Anti-Inflammatories from Arena"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
